Proven validity and management impact of amyloid imaging in Alzheimer's disease-repetita juvant
Eur J Nucl Med Mol Imaging
.
2020 Jul;47(8):1787-1790.
doi: 10.1007/s00259-020-04742-w.
Authors
Henryk Barthel
1
,
Javier Arbizu
2
,
Alexander Drzezga
3
4
5
,
Valentina Garibotto
6
,
Adriaan A Lammertsma
7
,
Silvia Morbelli
8
;
EANM Neuroimaging Committee
Collaborators
EANM Neuroimaging Committee
:
Nathalie Albert
,
Ronald Boellaard
,
Diego Cecchin
,
Ozgul Ekmekcioglu
,
Eric Guedj
,
Ian Law
,
Ivan Penuelas
,
Franck Semah
,
Tatjana Traub-Weidinger
,
Elsmarieke van de Giessen
,
Andrea Varrone
Affiliations
1
Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany.
[email protected]
.
2
Department of Nuclear Medicine, University of Navarra Clinic, Pamplona, Spain.
3
Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
4
German Centre for Neurodegenerative Diseases, Bonn-Cologne, Germany.
5
Molecular Organization of the Brain, Research Centre Jülich, Institute of Neuroscience and Medicine, Jülich, Germany.
6
Division of Nuclear Medicine and Molecular Imaging, Geneva University, Geneva, Switzerland.
7
VUMC Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
8
Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
PMID:
32130450
DOI:
10.1007/s00259-020-04742-w
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Alzheimer Disease*
Amyloid
Amyloid beta-Peptides
Humans
Substances
Amyloid
Amyloid beta-Peptides